VR Logo

Valneva SE - ADR download report


Healthcare | Biotechnology & Pharma Research

Valneva SE - ADR Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs.

IPO Date: 05-May-2021

Chairman of the Management Board, Pres & CEO: Mr. Thomas Lingelbach

Director Gen., Chief Bus. Officer & Member of Management Board: Mr. Franck Grimaud MBA

Listing: NASDAQ: VALN

Country: France

Headquarters: Saint-Herblain,

Website: https://valneva.com

Key Facts

Market cap: $1,288.66 Mln

Revenue (TTM): €24.29 Mln

Earnings (TTM): €-71.76 Mln

Cash: €0.00 Mln

Total Debt: €0.00 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $13.71 - 67.84

Shares outstanding: 53,828,600

10 Years Aggregate:

  • CFO: €182.41 Mln
  • EBITDA: €-96.26 Mln
  • Net Profit: €-282.80 Mln

Stock Performance

Time Period Valneva SE - ADR S&P BSE Sensex* S&P Small-Cap 600*
YTD-59.11-9.18-19.53
1 month-7.02-4.78-9.69
3 months-35.14-9.66-16.90
1 Year-13.560.81-17.67
3 Years--10.335.77
5 Years--11.345.69
10 Years--11.749.74
As on 30-Jun-2022 *As on 01-Jul-2022